Intravitreal Bevasizumab Versus Intravitreal Triamcinolone in Branch Retinal Vein Occlusion (BRVO)

Shahid Beheshti University of Medical Sciences

Status and phase: Unknown; Phase 2

Conditions: Branch Retinal Vein Occlusion

Treatments: Drug: Bevacizumab; Drug: Triamcinolone Acetonide

Study type: Interventional

Funder types: Other

Identifiers

NCT01044329

8900

Details and patient eligibility

About

This randomized clinical trial is conducted to evaluate the effect of three intravitreal injections of bevasizumab versus two intravitreal injections of triamcinolone in acute retinal vein occlusion. The outcomes are visual acuity and central macular thickness. The follow-up time is 6 months.

Enrollment: 90 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Recent onset (less than 3 months) BRVO

Exclusion criteria

• Any previous intervention

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

90 participants in 2 patient groups

Intravitreal bevacizumab

Active Comparator group

Treatment:

Drug: Bevacizumab

Intravitreal triamcinolone

Active Comparator group

Treatment:

Drug: Triamcinolone Acetonide